GCVC

GCVC is a research-stage vaccine candidate developed by Premas Biotech in collaboration with an undisclosed partner. The candidate is produced using Premas's proprietary D-Crypt™ platform, a recombinant protein expression system based on *Saccharomyces cerevisiae* (baker's yeast). This platform is specifically optimized for the production of difficult-to-express proteins, including multi-protein virus-like particles (VLPs) and membrane proteins. While the specific indication and molecular targets for GCVC have not been publicly revealed, the "GCVC" designation typically refers to a "Genetically Complex Vaccine Candidate," reflecting the company's focus on multi-antigenic or structurally sophisticated vaccine architectures. The program is currently in the early research phase of development and is listed as a distinct entry in the company's vaccine pipeline, separate from its COVID-19 and influenza programs.